TABLE 3.
Attitudes and Barriers Regarding MM Use
| All Providers (N = 288), Frequency (%) | Providers Legally ETC for MM (n = 96), Frequency (%) | Providers n-ETC for MM (n = 192), Frequency (%) | Unadjusted OR (95% CI) | Unadjusted P | Adjusted Model N | Adjusted ORa (95% CI) | Adjusted Pa | |
|---|---|---|---|---|---|---|---|---|
| Willing to help patients access MM | 240 of 261 (92) | 71 of 84 (85) | 169 of 177 (95) | 0.26 (0.1–0.65) | .0041 | 244 | 0.61 (0.17–2.15) | .44 |
| Approve of patients smoking MM | 133 of 234 (57) | 29 of 75 (39) | 104 of 159 (65) | 0.33 (0.19–0.59) | .0002 | 219 | 0.25 (0.11–0.55) | .0005 |
| Approve of patients using oral formulations of MM | 223 of 250 (89) | 56 of 76 (74) | 167 of 174 (96) | 0.12 (0.05–0.29) | <.0001 | 236 | 0.17 (0.05–0.53) | .0025 |
| Approve of using MM as cancer-directed therapy | 158 of 236 (67) | 19 of 80 (24) | 139 of 156 (89) | 0.04 (0.02–0.08) | <.0001 | 222 | 0.04 (0.01–0.09) | <.0001 |
| Approve of using MM to manage symptoms | 236 of 258 (92) | 67 of 82 (82) | 169 of 176 (96) | 0.19 (0.07–0.47) | .0004 | 244 | 0.16 (0.05–0.52) | .0026 |
| Favor clinical trials investigating MM use in children | 237 of 256 (93) | 80 of 85 (94) | 157 of 171 (92) | 1.43 (0.5–4.1) | .51 | — | — | — |
| Unconcerned about substance abuse among patients who receive MM | 162 of 259 (63) | 55 of 90 (61) | 107 of 169 (63) | 0.91 (0.54–1.54) | .73 | — | — | — |
| Unconcerned about prosecution for helping patients access MM | 208 of 260 (80) | 75 of 91 (82) | 133 of 169 (79) | 1.27 (0.66–2.44) | .48 | — | — | — |
—, not included in model.
a
In multivariate logistic regression, we compared ETC to n-ETC providers (reference group), adjusting for provider age, sex, race, and location of practice.